Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25101246 | 0.85 | PIK3CG (0.34) | PIK3CGEGFRDGAT1 | |
| SCHEMBL30211632 | 0.78 | PIK3CG (0.37) | PIK3CGEGFR | |
| SCHEMBL2629407 | 0.78 | PIK3CG (0.37) | PIK3CGEGFR | |
| SCHEMBL12132907 | 0.74 | PIK3CG (0.38) | PIK3CGEGFRDGAT1 | |
| SCHEMBL26797949 | 0.73 | EGFR (0.36) | EGFRDGAT1 | |
| SCHEMBL19432925 | 0.73 | PIK3CG (0.32) | PIK3CG | |
| SCHEMBL26795817 | 0.72 | BCHE (0.46) | — | |
| SCHEMBL25793171 | 0.72 | ALDH1A1 (0.35) | — | |
| SCHEMBL3292267 | 0.71 | PIK3CG (0.47) | PIK3CGEGFR | |
| SCHEMBL14024443 | 0.71 | PIK3CG (0.35) | PIK3CGEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382909-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382909-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230374008-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374008-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382909-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | PIK3CG 3060/4885EGFR 2452/4885DGAT1 2352/4885 |
| US-20230374008-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | PIK3CG 3060/4885EGFR 2452/4885DGAT1 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.